Stereotactic body radiation therapy for pulmonary metastasis of sarcoma is effective

Posted on

Stereotactic body radiation therapy (SBRT) is a potentially effective treatment for pulmonary metastasis of sarcoma, according to a study that found some patients who undergo SBRT achieve a durable response.

In this retrospective review, 39 patients (71 lesions) with oligometastatic/oligoprogressive disease or who were receiving palliation who were treated with SBRT were included.

Patients were followed for a median of 27.2 months.

Local control per tumor (LCpT) rates for the entire cohort were as follows:
-1 year: 100%
-2 years: 88.3%
-3 years: 73.6%

At 3 years, the local control per patient (LCpP) was 78.1%, the pulmonary progression-free rate was 22.7%, any progression-free rate was 12.9%, and overall survival was 83.7%.

Of the patients with oligometastasis, 5 (12.8%) had long-term disease-free intervals, with a median survival period of 40.7 months.

Oligoprogression, compared with oligometastasis, was associated with a worse prognosis, in addition to multiple pulmonary metastases and simultaneous extrathoracic metastasis.

Lee TH, Kim HJ, Kim JH, et al. Treatment outcomes of stereotactic body radiation therapy for pulmonary metastasis from sarcoma: a multicenter, retrospective study. Radiat Oncol. 2023;18(1):68. doi: 10.1186/s13014-023-02255-y. PMID: 37061679.